- Operating loss decreased from $4.4M in Q1 2024 to $4.1M in Q1 2025.
- Secured $2.6M through private placement of Series D convertible preferred stock.
- Regained Nasdaq compliance for minimum bid price requirement.
Windtree Therapeutics (WINT, Financial) announced their Q1 2025 financial results, reporting an operating loss of $4.1 million, a slight improvement from the $4.4 million loss in the same quarter of the previous year. As of March 31, 2025, the company held $1.2 million in cash and cash equivalents against $6.5 million in current liabilities.
In efforts to pivot towards revenue generation, Windtree has initiated several strategic actions. These include securing a right to purchase a 436-unit residential property in Houston and establishing a manufacturing partnership for PHEXXI®, anticipated to reduce production costs significantly. The company also aims to benefit from a China partnership expected to generate revenue by late 2026.
In Q1 2025, Windtree raised $2.6 million through a private placement of Series D convertible preferred stock. Despite recent financial maneuvering, the company remains under Nasdaq panel monitoring until March 2026 to ensure continued compliance with listing requirements.
Continued development of their lead asset, istaroxime, remains a focal point, with ongoing enrollment in the SCAI Stage C study for cardiogenic shock and an interim analysis expected in Q3 2025. This development aligns with their broader strategy of advancing their cardiology pipeline while generating immediate revenues through strategic acquisitions.
